Tags

Type your tag names separated by a space and hit enter

The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
Ann Neurol. 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4.AN

Abstract

Treatment-related dyskinesias are the major limitation of dopamine replacement therapies such as levodopa in Parkinson's disease (PD). Recent studies in parkinsonian, nonhuman primates have highlighted abnormalities in neural functioning that might underlie the generation of dyskinetic symptoms in patients with PD who have received prolonged dopaminergic therapy. This article reviews studies on metabolic activity in subregions of the basal ganglia which suggest that profound abnormalities in basal ganglia output may underlie levodopa-induced dyskinesia. Such abnormalities may result from changes within basal ganglia circuitry and may include either overt changes in average firing rate or modulation of the pattern of cell-cell communication within subregions of the basal ganglia circuitry. An appreciation of abnormalities in the mechanisms responsible for modulating synaptic transmission in the basal ganglia may suggest novel therapeutic approaches to the problem of dyskinesia.

Authors+Show Affiliations

Division of Neuroscience, School of Biological Sciences, University of Manchester, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10762137

Citation

Brotchie, J M.. "The Neural Mechanisms Underlying Levodopa-induced Dyskinesia in Parkinson's Disease." Annals of Neurology, vol. 47, no. 4 Suppl 1, 2000, pp. S105-12; discussion S112-4.
Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann Neurol. 2000;47(4 Suppl 1):S105-12; discussion S112-4.
Brotchie, J. M. (2000). The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Annals of Neurology, 47(4 Suppl 1), S105-12; discussion S112-4.
Brotchie JM. The Neural Mechanisms Underlying Levodopa-induced Dyskinesia in Parkinson's Disease. Ann Neurol. 2000;47(4 Suppl 1):S105-12; discussion S112-4. PubMed PMID: 10762137.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. A1 - Brotchie,J M, PY - 2000/4/13/pubmed PY - 2000/4/29/medline PY - 2000/4/13/entrez SP - S105-12; discussion S112-4 JF - Annals of neurology JO - Ann Neurol VL - 47 IS - 4 Suppl 1 N2 - Treatment-related dyskinesias are the major limitation of dopamine replacement therapies such as levodopa in Parkinson's disease (PD). Recent studies in parkinsonian, nonhuman primates have highlighted abnormalities in neural functioning that might underlie the generation of dyskinetic symptoms in patients with PD who have received prolonged dopaminergic therapy. This article reviews studies on metabolic activity in subregions of the basal ganglia which suggest that profound abnormalities in basal ganglia output may underlie levodopa-induced dyskinesia. Such abnormalities may result from changes within basal ganglia circuitry and may include either overt changes in average firing rate or modulation of the pattern of cell-cell communication within subregions of the basal ganglia circuitry. An appreciation of abnormalities in the mechanisms responsible for modulating synaptic transmission in the basal ganglia may suggest novel therapeutic approaches to the problem of dyskinesia. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/10762137/The_neural_mechanisms_underlying_levodopa_induced_dyskinesia_in_Parkinson's_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0364-5134&date=2000&volume=47&issue=4 Suppl 1&spage=S105 DB - PRIME DP - Unbound Medicine ER -